Shopping Cart
Remove All
Your shopping cart is currently empty
Elranatamab (PF-06863135) is a humanized bispecific antibody that targets BCMA (B-cell maturation antigen) on myeloma cells and CD3 on T cells. By targeting these molecules, Elranatamab activates T cells and directs them to induce a cytotoxic T cell response against myeloma cells. This compound is used in research for relapsed or refractory multiple myeloma.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $1,262 | 2-4 weeks | 2-4 weeks | |
| 5 mg | $3,535 | 2-4 weeks | 2-4 weeks |
| Description | Elranatamab (PF-06863135) is a humanized bispecific antibody that targets BCMA (B-cell maturation antigen) on myeloma cells and CD3 on T cells. By targeting these molecules, Elranatamab activates T cells and directs them to induce a cytotoxic T cell response against myeloma cells. This compound is used in research for relapsed or refractory multiple myeloma. |
| Synonyms | PF-06863135 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | < 1.0 EU/mg |
| Conjucates | Unconjugated |
| Target | BCAM/CD3 |
| Cas No. | 2408850-14-4 |
| Storage | -20°C for 1 year | Shipping with blue ice. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.